title: Aspirin use and risk of cholangiocarcinoma: External validation with big data.
authors.affiliation: Department of Medicine, Cleveland Clinic Fairview Hospital, Cleveland, OH.
authors.forename: Haider
authors.initials: H
authors.lastname: Altaii
authors.affiliation: Oncocardiology Program, Harrington Heart and Vascular Institute, University Hospitals of Cleveland and Case Western Reserve University, Cleveland, OH.
authors.forename: Sadeer G
authors.initials: SG
authors.lastname: Al-Kindi
authors.affiliation: Oncocardiology Program, Harrington Heart and Vascular Institute, University Hospitals of Cleveland and Case Western Reserve University, Cleveland, OH.
authors.forename: Guilherme H
authors.initials: GH
authors.lastname: Oliveira
authors.affiliation: Respiratory Institute, Cleveland Clinic, Cleveland, OH.
authors.forename: Zaid
authors.initials: Z
authors.lastname: Yaqoob
authors.affiliation: Department of Gastroenterology and Hepatology, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, OH.
authors.forename: Carlos
authors.initials: C
authors.lastname: Romero-Marrero
mesh_terms: D001241:Aspirin; D001650:Bile Duct Neoplasms; D001653:Bile Ducts, Intrahepatic; D018281:Cholangiocarcinoma; D006801:Humans
chemical_list: D001241:Aspirin